      |
||
Seth L. Harrison, M.D., Managing
General Partner
Greg Verdine, Ph.D. Joseph A. Yanchik III Joe joined Apple Tree Partners
in 2005. He currently is CEO
of Aileron Therapeutics, and a Director of Tokai Pharmaceuticals. Joe has fourteen years of experience founding,
funding, and developing technology companies. Prior to ATP, he was
a member of the senior management team at Mendel Biotechnology,
Inc., a private company funded by the Monsanto Company and the Biotechnology
Value Fund, which was named by the science journal Acumen one of
the 100 most important companies in the world in terms of its impact
on human health. Prior to Mendel, he helped found Poetic Genetics,
Inc., a gene therapy company based on discoveries out of the Stanford
University Medical Center that was subsequently funded by Bill Rutter
and his private development enterprise, Synergenics, and he was
a founding executive of a CMGI funded Internet company. Joe is a licensed attorney, admitted to practice
in New York, California, and the District of Columbia. His legal
practice included representing Fortune 500 companies while working
at Cahill Gordon & Reindel (NY) and Silicon Valley venture funded
start-ups while at Venture Law Group (Menlo Park). He received his
J.D. from Villanova University School of Law, at which he was Managing
Editor of the Law Review. Rosana joined Apple Tree Partners in August 2005. She is currently Vice President, Research for Aileron Therapeutics. Prior to joining ATP, Rosana was Director of Molecular and Cellular Biology at Millennium Pharmaceuticals, Inc., where she played a key role in the functional evaluation and advancement of novel drug targets into Millennium's drug discovery pipeline. Rosana has published over 20 peer-reviewed scientific articles and is inventor/co-inventor on over 100 patents. Rosana completed her post-doctoral training in 1996 at the Dana Farber Cancer Institute with Dr. Stephen Burakoff where she was a recipient of the David Abraham Fellowship in Pediatric Oncology. She received her Ph.D. in 1994 from Tufts University under the supervision of Dr. Lewis C. Cantley. Rosana obtained her Medical Degree in 1986 from the Universidade de Ciências Médicas, Rio de Janeiro, Brazil > Back to top Huw Nash, Ph.D. Huw joined Apple Tree Partners in June 2005. He
is currently Vice President, Corporate Development for Aileron
Therapeutics. Prior to joining ATP, Huw was a founding scientist
of NeoGenesis Pharmaceuticals, a drug-discovery technology company
that was acquired by Schering-Plough in February 2005. At NeoGenesis,
Huw served as Vice President, External Collaborations, where he
directly managed 21 research collaborations with large pharma and
biotech companies and academic labs, and also served as the principal
technical representative for all business development, private financing
and merger and acquisition activities. In addition, Huw was a Principal
Investigator for 3 Small Business Innovation Research Grants, was
a co-author of 5 peer-reviewed scientific publications with NeoGenesis,
and was a co-inventor on 9 patents. Huw received his B.A. in Biochemical
Sciences from Harvard College and received his Ph.D. in Organic
Chemistry from Harvard University with Professor Gregory L. Verdine. Marie-Thérèse is responsible for administration, financial management and operation of the funds, and she has been with Apple Tree Partners since its inception. Prior to joining ATP, Marie-Thérèse assisted Dr. Harrison at Oak Investment Partners. She received a Bachelor of Arts from Heerbrugg, Switzerland, a French graduate degree from Aix-en-Provence, France and a Certificate in Financial Analysis (CFA) from New York University.
SITRA |
||
 |